BioCryst Pharmaceuticals BCRX Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's pre-tax income?
- BioCryst Pharmaceuticals (BCRX) reported pre-tax income of -$720.81M in Q1 2026.
- How has BioCryst Pharmaceuticals's pre-tax income changed year-over-year?
- BioCryst Pharmaceuticals's pre-tax income decreased by 95193.4% year-over-year, from $758K to -$720.81M.
- What is the long-term trend for BioCryst Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's pre-tax income has grown at a 10.1% compound annual growth rate (CAGR), from -$181.81M to $267.39M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.